{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:11Z","timestamp":1792161071981,"version":"4.4.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11920-024-01577-2","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:31:07Z","timestamp":1734597067000},"page":"88-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-4400","authenticated-orcid":false,"given":"Jamarie","family":"Geller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-2687","authenticated-orcid":false,"given":"Eric","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13034-020-00329-3","volume":"14","author":"JM Fegert","year":"2020","unstructured":"Fegert JM, Vitiello B, Plener PL, Clemens V. Challenges and burden of the Coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: a narrative review to highlight clinical and research needs in the acute phase and the long return to normality. Child Adolesc Psychiatry Ment Health. 2020;14:20.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"1577_CR2","unstructured":"Office of the Surgeon General (OSG). Protecting Youth Mental Health: The U.S. Surgeon General\u2019s Advisory [Internet]. Washington (DC): US Department of Health and Human Services; 2021 [cited 2024 May 23]. (Publications and Reports of the Surgeon General). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK575984\/"},{"issue":"10","key":"1577_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","volume":"24","author":"GS Barber","year":"2022","unstructured":"Barber GS, Aaronson ST. The emerging field of psychedelic psychotherapy. Curr Psychiatry Rep. 2022;24(10):583\u201390.","journal-title":"Curr Psychiatry Rep"},{"key":"1577_CR4","doi-asserted-by":"publisher","unstructured":"O\u2019Connor K. As Psychedelic Research Advances, Can Youth Benefit? Psychiatr News [Internet]. 2024 Jan 22 [cited 2024 Jun 13]; https:\/\/psychnews-psychiatryonline-org.ezproxy.med.nyu.edu\/doi\/https:\/\/doi.org\/10.1176\/appi.pn.2024.02.2.5","DOI":"10.1176\/appi.pn.2024.02.2.5"},{"key":"1577_CR5","unstructured":"Major Depression - National Institute of Mental Health (NIMH). [Internet]. [cited 2023 Dec 21]. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression"},{"issue":"7","key":"1577_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1176\/appi.ajp.2010.09040552","volume":"167","author":"GJ Emslie","year":"2010","unstructured":"Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, et al. Treatment of resistant depression in adolescents (TORDIA): Week 24 outcomes. Am J Psychiatry. 2010;167(7):782\u201391.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1577_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archpsyc.64.10.1132","volume":"64","author":"JS March","year":"2007","unstructured":"March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The treatment for adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64(10):1132\u201343.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1577_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1176\/appi.ajp.2007.07091453","volume":"165","author":"GJ Emslie","year":"2008","unstructured":"Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, et al. Fluoxetine Versus Placebo in preventing relapse of Major Depression in Children and adolescents. Am J Psychiatry. 2008;165(4):459\u201367.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1577_CR9","first-page":"10732","volume":"71","author":"B Vitiello","year":"2010","unstructured":"Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a Follow-Up study of the TORDIA sample. J Clin Psychiatry. 2010;71(3):10732.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1577_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaac.2018.07.896","volume":"58","author":"ZM Clayborne","year":"2019","unstructured":"Clayborne ZM, Varin M, Colman I. Systematic review and Meta-analysis: adolescent depression and long-term psychosocial outcomes. J Am Acad Child Adolesc Psychiatry. 2019;58(1):72\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1577_CR11","doi-asserted-by":"crossref","unstructured":"Ivey-Stephenson AZ. Suicidal Ideation and Behaviors Among High School Students \u2014 Youth Risk Behavior Survey, United States, 2019. MMWR Suppl [Internet]. 2020 [cited 2023 Dec 21];69. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/su\/su6901a6.htm","DOI":"10.15585\/mmwr.su6901a6"},{"issue":"4","key":"1577_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00787-019-01341-5","volume":"29","author":"K Boylan","year":"2020","unstructured":"Boylan K, MacQueen G, Kirkpatrick R, Lee J, Santaguida PL. A systematic review of interventions for treatment resistant major depressive disorder in adolescents. Eur Child Adolesc Psychiatry. 2020;29(4):433\u201343.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"1577_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/chi.0b013e31802f5f03","volume":"46","author":"GJ Emslie","year":"2007","unstructured":"Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2007;46(4):479\u201388.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"1577_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/cap.2013.0146","volume":"24","author":"SD Atkinson","year":"2014","unstructured":"Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, et al. A double-blind efficacy and safety study of Duloxetine Flexible Dosing in Children and adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 2014;24(4):180\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1577_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jad.2019.07.084","volume":"258","author":"P Dhami","year":"2019","unstructured":"Dhami P, Knyahnytska Y, Atluri S, Lee J, Courtney DB, Croarkin PE, et al. Feasibility and clinical effects of theta burst stimulation in youth with major depressive disorders: an open-label trial. J Affect Disord. 2019;258:66\u201373.","journal-title":"J Affect Disord"},{"issue":"2","key":"1577_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-020-00829-y","volume":"46","author":"PE Croarkin","year":"2021","unstructured":"Croarkin PE, Elmaadawi AZ, Aaronson ST, Schrodt GR, Holbert RC, Verdoliva S, et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology. 2021;46(2):462\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1577_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.chc.2006.05.012","volume":"15","author":"D Stein","year":"2006","unstructured":"Stein D, Weizman A, Bloch Y. Electroconvulsive therapy and transcranial magnetic stimulation: can they be considered valid modalities in the treatment of pediatric mood disorders? Child Adolesc Psychiatr Clin. 2006;15(4):1035\u201356.","journal-title":"Child Adolesc Psychiatr Clin"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1744-859X-12-17","volume":"12","author":"NN Lima","year":"2013","unstructured":"Lima NN, Nascimento VB, Peixoto JA, Moreira MM, Neto ML, Almeida JC, et al. Electroconvulsive therapy use in adolescents: a systematic review. Ann Gen Psychiatry. 2013;12:17.","journal-title":"Ann Gen Psychiatry"},{"issue":"12","key":"1577_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/01.chi.0000142280.87429.68","volume":"43","author":"N Ghaziuddin","year":"2004","unstructured":"Ghaziuddin N, Kutcher SP, Knapp P. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(12):1521\u201339.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"102606","DOI":"10.1016\/j.nsa.2023.102606","volume":"2","author":"NC Albanese","year":"2023","unstructured":"Albanese NC, Reccagni A, Barezzi C, Marsili F, Poggini S, Branchi I. Social environment affects the vulnerability to adolescent-onset depression and determines antidepressant efficacy in a preclinical model. Neurosci Appl. 2023;2:102606.","journal-title":"Neurosci Appl"},{"key":"1577_CR21","doi-asserted-by":"publisher","first-page":"105012","DOI":"10.1016\/j.childyouth.2020.105012","volume":"113","author":"H Bang","year":"2020","unstructured":"Bang H, Won D, Park S. School engagement, self-esteem, and depression of adolescents: the role of sport participation and volunteering activity and gender differences. Child Youth Serv Rev. 2020;113:105012.","journal-title":"Child Youth Serv Rev"},{"issue":"7","key":"1577_CR22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaac.2016.04.016","volume":"55","author":"T Carter","year":"2016","unstructured":"Carter T, Morres ID, Meade O, Callaghan P. The effect of exercise on depressive symptoms in adolescents: a systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2016;55(7):580\u201390.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"1577_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1192\/bjp.bp.113.131227","volume":"204","author":"E Alisic","year":"2014","unstructured":"Alisic E, Zalta AK, van Wesel F, Larsen SE, Hafstad GS, Hassanpour K, et al. Rates of post-traumatic stress disorder in trauma-exposed children and adolescents: meta-analysis. Br J Psychiatry. 2014;204(5):335\u201340.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"1577_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0749-3797(98)00017-8","volume":"14","author":"VJ Felitti","year":"1998","unstructured":"Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and Household Dysfunction to many of the leading causes of death in adults: the adverse childhood experiences (ACE) study. Am J Prev Med. 1998;14(4):245\u201358.","journal-title":"Am J Prev Med"},{"issue":"10","key":"1577_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2215-0366(19)30286-X","volume":"6","author":"HP Hailes","year":"2019","unstructured":"Hailes HP, Yu R, Danese A, Fazel S. Long-term outcomes of childhood sexual abuse: an umbrella review. Lancet Psychiatry. 2019;6(10):830\u20139.","journal-title":"Lancet Psychiatry"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of Medical Psilocybin according to the 8 factors of the controlled substances Act. Neuropharmacology. 2018;142:143\u201366.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1577_CR27","first-page":"414","volume":"49","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Issues TWGOQ, Issues AWG. On Q. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(4):414\u201330.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"1577_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/cap.2009.0115","volume":"20","author":"AS Robb","year":"2010","unstructured":"Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2010;20(6):463\u201371.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"1577_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1017\/S0033291720002007","volume":"50","author":"RJB Bastien","year":"2020","unstructured":"Bastien RJB, Jongsma HE, Kabadayi M, Billings J. The effectiveness of psychological interventions for post-traumatic stress disorder in children, adolescents and young adults: a systematic review and meta-analysis. Psychol Med. 2020;50(10):1598\u2013612.","journal-title":"Psychol Med"},{"key":"1577_CR30","doi-asserted-by":"publisher","first-page":"100093","DOI":"10.1016\/j.jadr.2021.100093","volume":"4","author":"T Varker","year":"2021","unstructured":"Varker T, Jones KA, Arjmand HA, Hinton M, Hiles SA, Freijah I, et al. Dropout from guideline-recommended psychological treatments for posttraumatic stress disorder: a systematic review and meta-analysis. J Affect Disord Rep. 2021;4:100093.","journal-title":"J Affect Disord Rep"},{"key":"1577_CR31","doi-asserted-by":"crossref","unstructured":"Simmons C, Meiser-Stedman R, Baily H, Beazley P. A meta-analysis of dropout from evidence-based psychological treatment for post-traumatic stress disorder (PTSD) in children and young people. Eur J Psychotraumatology. 2021;12(1):1947570.","DOI":"10.1080\/20008198.2021.1947570"},{"issue":"1","key":"1577_CR32","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12913-022-08497-y","volume":"22","author":"AMS Skar","year":"2022","unstructured":"Skar AMS, Braathu N, Jensen TK, Ormhaug SM. Predictors of nonresponse and drop-out among children and adolescents receiving TF-CBT: investigation of client-, therapist-, and implementation factors. BMC Health Serv Res. 2022;22(1):1212.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"1577_CR33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025\u201333.","journal-title":"Nat Med"},{"issue":"10","key":"1577_CR34","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473\u201380.","journal-title":"Nat Med"},{"issue":"18","key":"1577_CR35","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of Major Depression. N Engl J Med. 2022;387(18):1637\u201348.","journal-title":"N Engl J Med"},{"issue":"9","key":"1577_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a Randomized Clinical Trial. JAMA. 2023;330(9):843\u201353.","journal-title":"JAMA"},{"issue":"4","key":"1577_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/bs13040297","volume":"13","author":"JJ Dawood Hristova","year":"2023","unstructured":"Dawood Hristova JJ, P\u00e9rez-Jover V. Psychotherapy with psilocybin for Depression: systematic review. Behav Sci. 2023;13(4):297.","journal-title":"Behav Sci"},{"key":"1577_CR38","unstructured":"What psychedelics legalisation. and decriminalisation looks like around the world [Internet]. [cited 2024 Nov 4]. https:\/\/www.bbc.com\/future\/article\/20240320-legal-status-of-psychedelics-around-the-world"},{"key":"1577_CR39","unstructured":"May N. A \u2018raft of unanswered questions\u2019 remain as Australia\u2019s first psychedelic therapy clinic opens. The Guardian [Internet]. 2024 Feb 10 [cited 2024 Nov 4]; https:\/\/www.theguardian.com\/australia-news\/2024\/feb\/11\/a-raft-of-unanswered-questions-remain-as-australias-first-psychedelic-therapy-clinic-opens"},{"issue":"12","key":"1577_CR40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol Oxf Engl. 2016;30(12):1259\u201367.","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"7","key":"1577_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol (Oxf). 2018;32(7):725\u201331.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1577_CR42","doi-asserted-by":"publisher","first-page":"866018","DOI":"10.3389\/fpsyg.2022.866018","volume":"13","author":"W Brennan","year":"2022","unstructured":"Brennan W, Belser AB. Models of psychedelic-assisted psychotherapy: a Contemporary Assessment and an introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Front Psychol. 2022;13:866018.","journal-title":"Front Psychol"},{"issue":"1","key":"1577_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48(1):104\u201312.","journal-title":"Neuropsychopharmacology"},{"issue":"7966","key":"1577_CR44","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","volume":"618","author":"R Nardou","year":"2023","unstructured":"Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790\u20138.","journal-title":"Nature"},{"issue":"10","key":"1577_CR45","first-page":"2948","volume":"26","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. Therapeutic Potential Psilocybin Molecules. 2021;26(10):2948.","journal-title":"Therapeutic Potential Psilocybin Molecules"},{"issue":"1","key":"1577_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/02791072.2022.2044096","volume":"55","author":"AT Hodge","year":"2023","unstructured":"Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC. The Use of Psilocybin in the Treatment of Psychiatric Disorders with attention to relative Safety Profile: a systematic review. J Psychoact Drugs. 2023;55(1):40\u201350.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"1577_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of Psychedelics are necessary for their Enduring Therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):568\u201372.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"1577_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268\u201383.","journal-title":"Psychopharmacology"},{"key":"1577_CR49","doi-asserted-by":"crossref","unstructured":"Haikazian S, Chen-Li DC, Johnson DE, Fancy F, Levinta A, Husain MI et al. Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res. 2023;115531.","DOI":"10.1016\/j.psychres.2023.115531"},{"issue":"2","key":"1577_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol (Oxf). 2022;36(2):151\u20138.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1577_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83\u2013102.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1577_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811221131997","volume":"37","author":"E Morton","year":"2023","unstructured":"Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of \u2018magic mushroom\u2019 consumption. J Psychopharmacol Oxf Engl. 2023;37(1):49.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"1577_CR53","doi-asserted-by":"publisher","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA Psychiatry [Internet]. 2023 Dec 6 [cited 2024 Mar 25]; https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4685","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"1577_CR54","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.jadr.2021.100240","volume":"6","author":"DE Gard","year":"2021","unstructured":"Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS, et al. Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep. 2021;6:100240.","journal-title":"J Affect Disord Rep"},{"issue":"3","key":"1577_CR55","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol Oxf Engl. 2015;29(3):280\u20138.","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"Suppl 1","key":"1577_CR56","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1192\/j.eurpsy.2022.837","volume":"65","author":"K Shah","year":"2022","unstructured":"Shah K, Trivedi C, Kamrai D, Akbar M, Tankersley W. Association of Psilocybin Use in adolescents with Major Depressive Episode. Eur Psychiatry. 2022;65(Suppl 1):S329.","journal-title":"Eur Psychiatry"},{"key":"1577_CR57","doi-asserted-by":"publisher","unstructured":"Simonsson O, Mosing MA, Osika W, Ull\u00e9n F, Larsson H, Lu Y et al. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry [Internet]. 2024 Mar 13 [cited 2024 Apr 2]; https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0047","DOI":"10.1001\/jamapsychiatry.2024.0047"},{"key":"1577_CR58","doi-asserted-by":"publisher","first-page":"749068","DOI":"10.3389\/fphar.2021.749068","volume":"12","author":"A Markopoulos","year":"2022","unstructured":"Markopoulos A, Inserra A, De Gregorio D, Gobbi G. Evaluating the potential use of Serotonergic Psychedelics in Autism Spectrum Disorder. Front Pharmacol. 2022;12:749068.","journal-title":"Front Pharmacol"},{"key":"1577_CR59","doi-asserted-by":"publisher","unstructured":"Bender L, Goldschmidt L, Sankar DVS, Freedman AM. Treatment of Autistic Schizophrenic Children with LSD-25 and UML-491. In: Wortis J, editor. Recent Advances in Biological Psychiatry [Internet]. Boston, MA: Springer US; 1962 [cited 2024 Jun 13]. pp. 170\u20139. http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-1-4684-8306-2_17","DOI":"10.1007\/978-1-4684-8306-2_17"},{"issue":"10","key":"1577_CR60","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/JCMA.0000000000001150","volume":"87","author":"MH Chen","year":"2024","unstructured":"Chen MH, Su TP, Hsu JW, Tsai SJ. Autism, youth suicide, and psychedelics: a review of the 21st century evidence. J Chin Med Assoc. 2024;87(10):904.","journal-title":"J Chin Med Assoc"},{"key":"1577_CR61","unstructured":"Lykos Therapeutics - News. Release Archive [Internet]. [cited 2024 Jun 14]. Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD. https:\/\/news.lykospbc.com\/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD"},{"issue":"4","key":"1577_CR62","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-Assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with Meta-analysis. J Clin Pharmacol. 2022;62(4):463\u201371.","journal-title":"J Clin Pharmacol"},{"key":"1577_CR63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5929","key":"1577_CR64","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1126\/science.1167975","volume":"324","author":"MH Monfils","year":"2009","unstructured":"Monfils MH, Cowansage KK, Klann E, LeDoux JE. Extinction-reconsolidation boundaries: Key to Persistent Attenuation of Fear Memories. Science. 2009;324(5929):951\u20135.","journal-title":"Science"},{"issue":"8","key":"1577_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp. 2001;16(8):589\u201398.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1577_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/PRBM.S10380","volume":"4","author":"G H\u00f6gberg","year":"2011","unstructured":"H\u00f6gberg G, Nardo D, H\u00e4llstr\u00f6m T, Pagani M. Affective psychotherapy in post-traumatic reactions guided by affective neuroscience: memory reconsolidation and play. Psychol Res Behav Manag. 2011;4:87\u201396.","journal-title":"Psychol Res Behav Manag"},{"issue":"3","key":"1577_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jcph.266","volume":"54","author":"C Michael White","year":"2014","unstructured":"Michael White C. How MDMA\u2019s pharmacology and pharmacokinetics drive desired effects and harms. J Clin Pharmacol. 2014;54(3):245\u201352.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1577_CR68","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/02698811211055809","volume":"36","author":"B Sessa","year":"2022","unstructured":"Sessa B, Aday JS, O\u2019Brien S, Curran HV, Measham F, Higbed L, et al. Debunking the myth of Blue mondays: no evidence of affect drop after taking clinical MDMA. J Psychopharmacol Oxf Engl. 2022;36(3):360\u20137.","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"6","key":"1577_CR69","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/brain\/awq103","volume":"133","author":"SJ Kish","year":"2010","unstructured":"Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, et al. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography\/[11\u00a0C]DASB and structural brain imaging study. Brain. 2010;133(6):1779\u201397.","journal-title":"Brain"},{"issue":"7","key":"1577_CR70","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1360-0443.2011.03437.x","volume":"106","author":"AC Parrott","year":"2011","unstructured":"Parrott AC. Residual neurocognitive features of Ecstasy Use: a re-interpretation of Halpern Et Al. (2011) consistent with serotonergic neurotoxicity. Addiction. 2011;106(7):1365\u20131268.","journal-title":"Addiction"},{"issue":"4","key":"1577_CR71","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1360-0443.2010.03252.x","volume":"106","author":"JH Halpern","year":"2011","unstructured":"Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, Pope HG. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addict Abingdon Engl. 2011;106(4):777\u201386.","journal-title":"Addict Abingdon Engl"},{"key":"1577_CR72","doi-asserted-by":"crossref","unstructured":"McCann UD, Ricaurte GA. Chapter Fifteen - Effects of MDMA on the Human Nervous System. In: Madras B, Kuhar M, editors. The Effects of Drug Abuse on the Human Nervous System [Internet]. Boston: Academic Press; 2014 [cited 2023 Dec 22]. pp. 475\u201397. https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780124186798000150","DOI":"10.1016\/B978-0-12-418679-8.00015-0"},{"key":"1577_CR73","doi-asserted-by":"publisher","first-page":"113888","DOI":"10.1016\/j.expneurol.2021.113888","volume":"347","author":"C Montgomery","year":"2022","unstructured":"Montgomery C, Roberts CA. Neurological and cognitive alterations induced by MDMA in humans. Exp Neurol. 2022;347:113888.","journal-title":"Exp Neurol"},{"issue":"4","key":"1577_CR74","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of \u00b1\u20093,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxf). 2011;25(4):439\u201352.","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"9","key":"1577_CR75","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.bbadis.2016.06.016","volume":"1862","author":"S Abad","year":"2016","unstructured":"Abad S, Ramon C, Pubill D, Camarasa J, Camins A, Escubedo E. Adolescent exposure to MDMA induces dopaminergic toxicity in substantia nigra and potentiates the amyloid plaque deposition in the striatum of APPswe\/PS1dE9 mice. Biochim Biophys Acta BBA - Mol Basis Dis. 2016;1862(9):1815\u201326.","journal-title":"Biochim Biophys Acta BBA - Mol Basis Dis"},{"key":"1577_CR76","doi-asserted-by":"publisher","unstructured":"Kangaslampi S, Zijlmans J. MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations. Eur Child Adolesc Psychiatry [Internet]. 2023 Oct 10 [cited 2024 May 11]; https:\/\/doi.org\/10.1007\/s00787-023-02310-9","DOI":"10.1007\/s00787-023-02310-9"},{"key":"1577_CR77","doi-asserted-by":"crossref","unstructured":"Pantoni MM, Anagnostaras SG. Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose. Esbenshade TA, editor. Pharmacol Rev. 2019;71(3):413\u201349.","DOI":"10.1124\/pr.118.017087"},{"issue":"3","key":"1577_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00213-003-1679-4","volume":"173","author":"LK Jacobsen","year":"2004","unstructured":"Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Preliminary evidence of hippocampal dysfunction in adolescent MDMA (ecstasy) users: possible relationship to neurotoxic effects. Psychopharmacology. 2004;173(3):383\u201390.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1577_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/0269881107078293","volume":"22","author":"RS Falck","year":"2008","unstructured":"Falck RS, Jichuan Wang, Carlson RG. Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis. J Psychopharmacol (Oxf). 2008;22(1):47\u201354.","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"5","key":"1577_CR80","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/eurpub\/cku062","volume":"24","author":"M McCann","year":"2014","unstructured":"McCann M, Higgins K, Perra O, McCartan C, McLaughlin A. Adolescent ecstasy use and depression: cause and effect, or two outcomes of home environment? Eur J Public Health. 2014;24(5):845\u201350.","journal-title":"Eur J Public Health"},{"key":"1577_CR81","doi-asserted-by":"publisher","first-page":"173021","DOI":"10.1016\/j.pbb.2020.173021","volume":"198","author":"A Acheson","year":"2020","unstructured":"Acheson A. Behavioral processes and risk for problem substance use in adolescents. Pharmacol Biochem Behav. 2020;198:173021.","journal-title":"Pharmacol Biochem Behav"},{"key":"1577_CR82","unstructured":"Jeffrey JK, Weintraub MJ, Grob CS. Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution. J Am Acad Child Adolesc Psychiatry [Internet]. 2024 May 8 [cited 2024 Jun 9];0(0). https:\/\/www.jaacap.org\/article\/S0890-8567(24)00241-7\/fulltext"},{"issue":"2","key":"1577_CR83","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10567-013-0156-9","volume":"17","author":"S Matulis","year":"2014","unstructured":"Matulis S, Resick PA, Rosner R, Steil R. Developmentally adapted cognitive Processing Therapy for adolescents suffering from posttraumatic stress disorder after Childhood sexual or physical abuse: a pilot study. Clin Child Fam Psychol Rev. 2014;17(2):173\u201390.","journal-title":"Clin Child Fam Psychol Rev"},{"issue":"6","key":"1577_CR84","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1080\/10503307.2021.2011983","volume":"32","author":"KS Ovenstad","year":"2022","unstructured":"Ovenstad KS, Jensen TK, Ormhaug SM. Four perspectives on traumatized youths\u2019 therapeutic alliance: correspondence and outcome predictions. Psychother Res. 2022;32(6):820\u201332.","journal-title":"Psychother Res"},{"issue":"4","key":"1577_CR85","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.cpr.2009.02.005","volume":"29","author":"K Restifo","year":"2009","unstructured":"Restifo K, B\u00f6gels S. Family processes in the development of youth depression: translating the evidence to treatment. Clin Psychol Rev. 2009;29(4):294\u2013316.","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"1577_CR86","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10567-005-6666-3","volume":"8","author":"JB Sander","year":"2005","unstructured":"Sander JB, McCarty CA. Youth depression in the family context: familial risk factors and models of treatment. Clin Child Fam Psychol Rev. 2005;8(3):203\u201319.","journal-title":"Clin Child Fam Psychol Rev"},{"issue":"4","key":"1577_CR87","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.pcl.2022.04.011","volume":"69","author":"NM Goodrum","year":"2022","unstructured":"Goodrum NM, Prinz RJ. Family-based Prevention of Child traumatic stress. Pediatr Clin North Am. 2022;69(4):633\u201344.","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"1577_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10802-018-0445-3","volume":"47","author":"RT Liu","year":"2019","unstructured":"Liu RT. Childhood maltreatment and impulsivity: a Meta-analysis and recommendations for future study. J Abnorm Child Psychol. 2019;47(2):221\u201343.","journal-title":"J Abnorm Child Psychol"},{"key":"1577_CR89","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.crbeha.2023.100102","volume":"4","author":"L Burback","year":"2023","unstructured":"Burback L, Dhaliwal R, Reeson M, Erick T, Hartle K, Chow E, et al. Trauma focused psychotherapy in patients with suicidal ideation: a scoping review. Curr Res Behav Sci. 2023;4:100102.","journal-title":"Curr Res Behav Sci"},{"key":"1577_CR90","doi-asserted-by":"publisher","unstructured":"O\u2019Donnell KC, Okano L, Alpert M, Nicholas CR, Thomas C, Poulter B et al. The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD. Front Psychol [Internet]. 2024 Nov 4 [cited 2024 Nov 5];15. https:\/\/www.frontiersin.org\/journals\/psychology\/articles\/https:\/\/doi.org\/10.3389\/fpsyg.2024.1427531\/full","DOI":"10.3389\/fpsyg.2024.1427531\/full"},{"key":"1577_CR91","doi-asserted-by":"crossref","unstructured":"Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. J Med Ethics. 2021;47(12):807\u201314.","DOI":"10.1136\/medethics-2020-106070"},{"key":"1577_CR92","doi-asserted-by":"publisher","first-page":"737738","DOI":"10.3389\/fpsyt.2021.737738","volume":"12","author":"ML Williams","year":"2021","unstructured":"Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O\u2019Carroll S, et al. Translating psychedelic therapies from clinical trials to community clinics: building bridges and addressing potential challenges ahead. Front Psychiatry. 2021;12:737738.","journal-title":"Front Psychiatry"},{"issue":"6","key":"1577_CR93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","volume":"81","author":"M Marks","year":"2024","unstructured":"Marks M, Brendel RW, Shachar C, Cohen IG. Essentials of informed consent to psychedelic medicine. JAMA Psychiatry. 2024;81(6):611\u20137.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"1577_CR94","first-page":"471","volume":"43","author":"TB Harris","year":"2020","unstructured":"Harris TB, Udoetuk SC, Webb S, Tatem A, Nutile LM, Al-Mateen CS. Achiev Mental Health Equity: Child Adolescents Psychiatr Clin. 2020;43(3):471\u201385.","journal-title":"Achiev Mental Health Equity: Child Adolescents Psychiatr Clin"},{"issue":"1","key":"1577_CR95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245.","journal-title":"BMC Psychiatry"},{"key":"1577_CR96","doi-asserted-by":"publisher","first-page":"109127","DOI":"10.1016\/j.neuropharm.2022.109127","volume":"214","author":"CE Ortiz","year":"2022","unstructured":"Ortiz CE, Dourron HM, Sweat NW, Garcia-Romeu A, MacCarthy S, Anderson BT, et al. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology. 2022;214:109127.","journal-title":"Neuropharmacology"},{"key":"1577_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.socscimed.2013.06.032","volume":"103","author":"JM Metzl","year":"2014","unstructured":"Metzl JM, Hansen H. Structural competency: theorizing a new medical engagement with stigma and inequality. Soc Sci Med. 2014;103:126\u201333.","journal-title":"Soc Sci Med"},{"key":"1577_CR98","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.neuropharm.2022.109214","volume":"219","author":"SJ Belouin","year":"2022","unstructured":"Belouin SJ, Averill LA, Henningfield JE, Xenakis SN, Donato I, Grob CS, et al. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology. 2022;219:109214.","journal-title":"Neuropharmacology"},{"key":"1577_CR99","unstructured":"Miech RA, Johnston LD, Patrick ME, O\u2019Malley PM, Bachman JG. Overview and Detailed Results for Secondary School Students."}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-024-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-024-01577-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-024-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:11:40Z","timestamp":1737987100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-024-01577-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s11920-024-01577-2","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"4 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I am involved in clinical research involving psilocybin-assisted psychotherapy at the University of Michigan, funded by COMPASS Pathways and the Department of Anesthesia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}